$HYEX
HEALTHY EXTRACTS INC.

2023 Q3 Form 10-Q Financial Statement

#000109690623001602 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $613.5K $588.5K $818.6K
YoY Change 22.79% 25.26% 21.89%
Cost Of Revenue $120.3K $303.4K $401.1K
YoY Change 75.51% 55.16% 101.86%
Gross Profit $493.2K $285.1K $417.5K
YoY Change 14.41% 3.94% -11.71%
Gross Profit Margin 80.39% 48.44% 51.0%
Selling, General & Admin $754.0K $1.541M $538.8K
YoY Change 55.29% 60.34% -24.16%
% of Gross Profit 152.88% 540.55% 129.04%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $550.00 $550.00 $550.00
YoY Change 66.67% -56.69%
% of Gross Profit 0.11% 0.19% 0.13%
Operating Expenses $754.0K $1.541M $538.8K
YoY Change 55.29% 73.45% -24.16%
Operating Profit -$260.8K -$1.256M -$121.3K
YoY Change 378.78% 104.49% -48.94%
Interest Expense $12.87K -$11.36K $240.8K
YoY Change -111.12% -95.37% -79.92%
% of Operating Profit
Other Income/Expense, Net $12.87K -$11.36K
YoY Change -111.12% -95.37%
Pretax Income -$247.9K -$1.267M $43.42K
YoY Change 45.65% 47.47% -91.91%
Income Tax
% Of Pretax Income
Net Earnings -$247.9K -$1.267M $43.42K
YoY Change 45.65% 47.47% -91.91%
Net Earnings / Revenue -40.41% -215.34% 5.3%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.09 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 345.5M shares 345.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.39K $92.50K $65.65K
YoY Change -37.21% -41.97% -70.44%
Cash & Equivalents $46.39K $92.50K $65.65K
Short-Term Investments
Other Short-Term Assets $221.5K $219.3K $0.00
YoY Change
Inventory $1.528M $1.465M $1.819M
Prepaid Expenses
Receivables $109.2K $114.9K $105.8K
Other Receivables $0.00 $34.50K $0.00
Total Short-Term Assets $1.905M $1.925M $1.991M
YoY Change -6.68% -9.56% -13.95%
LONG-TERM ASSETS
Property, Plant & Equipment $3.860K $4.400K $5.500K
YoY Change -36.2% -33.33% 428.85%
Goodwill $193.3K $193.3K $193.3K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $16.89K $16.89K $69.90K
YoY Change 0.0% 0.0%
Total Long-Term Assets $735.9K $737.0K $790.5K
YoY Change -0.3% -0.22% 10.38%
TOTAL ASSETS
Total Short-Term Assets $1.905M $1.925M $1.991M
Total Long-Term Assets $735.9K $737.0K $790.5K
Total Assets $2.641M $2.662M $2.781M
YoY Change -4.99% -7.15% -8.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $68.54K $112.3K $91.32K
YoY Change -39.92% -1.59% 145.03%
Accrued Expenses $188.8K $28.67K $94.55K
YoY Change 415.62% 268.35% 59.55%
Deferred Revenue
YoY Change
Short-Term Debt $1.081M $1.024M $593.5K
YoY Change 137.61% 101.47% 73.23%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.616M $1.481M $902.8K
YoY Change 71.15% 65.3% 61.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $26.19K $47.41K
YoY Change
Total Long-Term Liabilities $26.19K $47.41K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.616M $1.481M $902.8K
Total Long-Term Liabilities $26.19K $47.41K $0.00
Total Liabilities $1.616M $1.481M $902.8K
YoY Change 71.15% 65.3% 61.55%
SHAREHOLDERS EQUITY
Retained Earnings -$18.02M -$17.77M -$15.93M
YoY Change 12.49% 6.58%
Common Stock $354.5K $345.5K $345.2K
YoY Change 0.29% 2.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.024M $1.181M $1.878M
YoY Change
Total Liabilities & Shareholders Equity $2.641M $2.662M $2.781M
YoY Change -4.99% -7.15% -8.2%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$247.9K -$1.267M $43.42K
YoY Change 45.65% 47.47% -91.91%
Depreciation, Depletion And Amortization $550.00 $550.00 $550.00
YoY Change 66.67% -56.69%
Cash From Operating Activities -$67.88K -$93.23K -$93.94K
YoY Change -21.38% 101.49% -329.79%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.77K -27.47K 85.71K
YoY Change 2554.88% -124.23% 11.02%
NET CHANGE
Cash From Operating Activities -67.88K -93.23K -93.94K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 21.77K -27.47K 85.71K
Net Change In Cash -46.11K -120.7K -8.230K
YoY Change -46.08% -279.83% -107.69%
FREE CASH FLOW
Cash From Operating Activities -$67.88K -$93.23K -$93.94K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$67.88K -$93.23K -$93.94K
YoY Change -21.38% 101.49% -280.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55572
dei Entity Registrant Name
EntityRegistrantName
Healthy Extracts Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2594704
dei Entity Address Address Line1
EntityAddressAddressLine1
7375 Commercial Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 125
dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89011
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
463-1004
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
345492442 shares
CY2023Q2 us-gaap Cash
Cash
92501 usd
CY2022Q4 us-gaap Cash
Cash
65651 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
114900 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
105794 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
1464625 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1819128 usd
CY2023Q2 us-gaap Acquisition Costs Cumulative
AcquisitionCostsCumulative
118632 usd
CY2022Q4 us-gaap Acquisition Costs Cumulative
AcquisitionCostsCumulative
53015 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100623 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2023Q2 us-gaap Notes Receivable Net
NotesReceivableNet
34500 usd
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
0 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
1925214 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2043587 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4403 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5501 usd
CY2023Q2 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
521881 usd
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
521881 usd
CY2023Q2 us-gaap Deposits Assets
DepositsAssets
16890 usd
CY2022Q4 us-gaap Deposits Assets
DepositsAssets
16890 usd
CY2023Q2 us-gaap Goodwill
Goodwill
193260 usd
CY2022Q4 us-gaap Goodwill
Goodwill
193260 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
736434 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
737531 usd
CY2023Q2 us-gaap Assets
Assets
2662214 usd
CY2022Q4 us-gaap Assets
Assets
2781118 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
112326 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
91316 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28672 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
94554 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56139 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47409 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
427359 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
275370 usd
CY2023Q2 fil Notes Payable Related Party
NotesPayableRelatedParty
866 usd
CY2022Q4 fil Notes Payable Related Party
NotesPayableRelatedParty
866 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
595638 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
317284 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
39942 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
21387 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
173069 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
102011 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1481418 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
902788 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
345492442 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
345492442 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
345172442 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
345172442 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
345492 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
345172 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18608436 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17459899 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17773134 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15926742 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1180795 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1878330 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2662214 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2781118 usd
CY2023Q2 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
588484 usd
CY2022Q2 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
469812 usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
1203427 usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
933198 usd
CY2023Q2 us-gaap Revenues
Revenues
588484 usd
CY2022Q2 us-gaap Revenues
Revenues
469812 usd
us-gaap Revenues
Revenues
1203427 usd
us-gaap Revenues
Revenues
933198 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
303415 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
195556 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
640517 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
334238 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
303415 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
195556 usd
us-gaap Cost Of Revenue
CostOfRevenue
640517 usd
us-gaap Cost Of Revenue
CostOfRevenue
334238 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
285069 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
274255 usd
us-gaap Gross Profit
GrossProfit
562911 usd
us-gaap Gross Profit
GrossProfit
598960 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1540942 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
888401 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2223972 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1258758 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1540942 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
888401 usd
us-gaap Operating Expenses
OperatingExpenses
2223972 usd
us-gaap Operating Expenses
OperatingExpenses
1258758 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-25212 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-24365 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-114272 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-57322 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
13850 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-220817 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-71058 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-141839 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 usd
CY2022Q2 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
2643 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11362 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-245181 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-185331 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-196517 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1267235 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-859326 usd
us-gaap Profit Loss
ProfitLoss
-1846392 usd
us-gaap Profit Loss
ProfitLoss
-856315 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1267235 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-859326 usd
us-gaap Net Income Loss
NetIncomeLoss
-1846392 usd
us-gaap Net Income Loss
NetIncomeLoss
-856315 usd
CY2023Q2 fil Loss Per Share Basic And Diluted
LossPerShareBasicAndDiluted
-0.00
CY2022Q2 fil Loss Per Share Basic And Diluted
LossPerShareBasicAndDiluted
-0.00
fil Loss Per Share Basic And Diluted
LossPerShareBasicAndDiluted
-0.01
fil Loss Per Share Basic And Diluted
LossPerShareBasicAndDiluted
-0.00
CY2023Q2 fil Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
345377525 shares
CY2022Q2 fil Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
339980360 shares
fil Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
345435456 shares
fil Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
342254631 shares
us-gaap Net Income Loss
NetIncomeLoss
-1846392 usd
us-gaap Net Income Loss
NetIncomeLoss
-856315 usd
fil Depreciation And Amortization1
DepreciationAndAmortization1
1098 usd
fil Depreciation And Amortization1
DepreciationAndAmortization1
-219 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1148857 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
422300 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
71058 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
141839 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9106 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-33148 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-354503 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-88877 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
65617 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0 usd
fil Increase Decrease In Right Of Use Asset Net
IncreaseDecreaseInRightOfUseAssetNet
-100623 usd
fil Increase Decrease In Right Of Use Asset Net
IncreaseDecreaseInRightOfUseAssetNet
0 usd
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
0 usd
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-16890 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-34500 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
21011 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
76874 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-65883 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-51479 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
18555 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1633 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2913 usd
fil Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
56139 usd
fil Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
0 usd
fil Increase Decrease In Operating Lease Liability Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent
47409 usd
fil Increase Decrease In Operating Lease Liability Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-403493 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157319 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7987 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2643 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5344 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-65617 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
350000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
539000 usd
fil Payments For Repayment Of Convertible Debt
PaymentsForRepaymentOfConvertibleDebt
110535 usd
fil Payments For Repayment Of Convertible Debt
PaymentsForRepaymentOfConvertibleDebt
203413 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
431000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-309011 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
0 usd
fil Proceeds From Issuance Of Notes Payable Related Party
ProceedsFromIssuanceOfNotesPayableRelatedParty
0 usd
fil Proceeds From Issuance Of Notes Payable Related Party
ProceedsFromIssuanceOfNotesPayableRelatedParty
-170000 usd
us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
68888 usd
us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
430342 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99970 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26850 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62693 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65651 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
222098 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92501 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159405 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2470738 usd
CY2022 fil Cancelation Of Common Stock For Debt
CancelationOfCommonStockForDebt
-53813 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
427496 usd
CY2022 fil Issuance Of Common Stock Note Conversion
IssuanceOfCommonStockNoteConversion
17031 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-983121 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1878330 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16000 usd
fil Fair Value Of Vested Restricted Stock Units
FairValueOfVestedRestrictedStockUnits
445000 usd
fil Fair Value Of Unvested Restricted Stock Units
FairValueOfUnvestedRestrictedStockUnits
76047 usd
fil Fair Value Of Options And Warrants Issued
FairValueOfOptionsAndWarrantsIssued
611810 usd
us-gaap Net Income Loss
NetIncomeLoss
-1846392 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1180795 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font:10pt stHtmlOvrFontNm;margin:0"><b><i>Use of Estimates</i></b></p> <p style="font:10pt stHtmlOvrFontNm;margin:0"> </p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"> </p> <p style="font:11pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="font-size:10pt">In regards to inventory write-offs and allowances, our Company determines the net realizable value by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked. </span></p> <p style="font:11pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify">As for revenue adjustments for discounts, allowances and refunds, we treat each of these items differently. When it comes to revenue discounts, we will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that we will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, we book this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to our refund percentage is less than 1% we decided the need for an estimated adjustment for allowances and refunds was not material. If we do receive any returned orders, we will directly book those orders as refunds the day we receive the call from the customer requesting the refund. We will book the credit memo at the full value of the customer original order.</p>
CY2023Q2 fil Inventory Allowances
InventoryAllowances
1914891 usd
CY2022Q2 fil Inventory Allowances
InventoryAllowances
1914891 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
3087777 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3398655 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
285993 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
310600 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
5816 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
24764 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
3379516 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
3734019 usd
CY2023Q2 fil Inventory Allowances
InventoryAllowances
1914891 usd
CY2022Q4 fil Inventory Allowances
InventoryAllowances
1914891 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
1464625 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1819128 usd
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
35837 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font:10pt stHtmlOvrFontNm;margin:0;text-align:justify"><b><i>Concentration</i></b></p> <p style="font:10pt stHtmlOvrFontNm;margin:0;margin-left:36pt;color:#000000;text-align:justify"> </p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF">There is no concentration of revenue for the months ended June 30, 2022 and for the months ended June 30, 2023.  The Company doesn’t have any customer with a percentage of revenue more than 10%.</span></p>
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
92527 usd
CY2022 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
9484 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
102011 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
71058 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
173069 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
173069 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
102011 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
92527 usd
CY2022 fil Convertible Debt Issued
ConvertibleDebtIssued
264952 usd
CY2022 fil Derivative Liabilities Debt Premium
DerivativeLiabilitiesDebtPremium
-43269 usd
CY2022 fil Convertible Debt Change In Fair Value Recognized In Operations
ConvertibleDebtChangeInFairValueRecognizedInOperations
-212199 usd
CY2022 fil Convertible Debt Converted
ConvertibleDebtConverted
0 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
102011 usd
fil Convertible Debt Issued
ConvertibleDebtIssued
145067 usd
fil Derivative Liabilities Debt Premium
DerivativeLiabilitiesDebtPremium
29167 usd
fil Convertible Debt Change In Fair Value Recognized In Operations
ConvertibleDebtChangeInFairValueRecognizedInOperations
-35837 usd
fil Convertible Debt Converted
ConvertibleDebtConverted
-38172 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
173069 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
38172 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
us-gaap Net Income Loss
NetIncomeLoss
17725470 usd
CY2023Q2 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
0 usd
CY2022Q2 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
1000 usd
CY2023Q2 us-gaap Capital Leases Contingent Rental Payments Due
CapitalLeasesContingentRentalPaymentsDue
5333 usd
CY2023Q2 fil Capital Leases Contingent Rental Payments Due Next24 Months
CapitalLeasesContingentRentalPaymentsDueNext24Months
5694 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
us-gaap Lease Cost
LeaseCost
0 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.098 pure
CY2023Q2 fil Right Of Use Assets Net Of Amortization
RightOfUseAssetsNetOfAmortization
100623 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56139 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47409 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
103547 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
33449 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
69635 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5822 usd
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
108906 usd
CY2023Q2 us-gaap Receivable With Imputed Interest Discount
ReceivableWithImputedInterestDiscount
5359 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
103547 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
7549 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
5007 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
52933 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
42329 usd
fil Origination Fees
OriginationFees
68888 usd
fil Origination Fees
OriginationFees
20000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-114272 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-57322 usd
CY2022 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
212199 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
92527 usd
CY2022 fil Convertible Debt Issued
ConvertibleDebtIssued
264952 usd
CY2022 fil Derivative Liabilities Debt Premium
DerivativeLiabilitiesDebtPremium
-43269 usd
CY2022 fil Convertible Debt Change In Fair Value Recognized In Operations
ConvertibleDebtChangeInFairValueRecognizedInOperations
-212199 usd
CY2022 fil Convertible Debt Converted
ConvertibleDebtConverted
0 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
102011 usd
fil Convertible Debt Issued
ConvertibleDebtIssued
145067 usd
fil Derivative Liabilities Debt Premium
DerivativeLiabilitiesDebtPremium
29167 usd
fil Convertible Debt Change In Fair Value Recognized In Operations
ConvertibleDebtChangeInFairValueRecognizedInOperations
-35837 usd
fil Convertible Debt Converted
ConvertibleDebtConverted
-38172 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
173069 usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
508880 usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-179826 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-508880 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
179826 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
508880 usd
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
179826 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
508880 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
179826 usd
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company effectuated a reverse stock split of 1-for-250 as of July 23, 2018
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
fil Warrants Issued
WarrantsIssued
7421544 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23421544 shares
CY2023Q2 fil Warrants Fully Vested
WarrantsFullyVested
16000000 shares
fil Fair Value Of Vested Restricted Stock Units
FairValueOfVestedRestrictedStockUnits
445000 usd
CY2023Q2 fil Unvested Compensation Related To Issuances Of Restricted Stock Units Fair Value
UnvestedCompensationRelatedToIssuancesOfRestrictedStockUnitsFairValue
298153 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0518 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0275 pure
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y9M
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.290 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.948 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure

Files In Submission

Name View Source Status
0001096906-23-001602-index-headers.html Edgar Link pending
0001096906-23-001602-index.html Edgar Link pending
0001096906-23-001602.txt Edgar Link pending
0001096906-23-001602-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hyex-20230630.htm Edgar Link pending
hyex-20230630.xsd Edgar Link pending
hyex10q_1.jpg Edgar Link pending
hyex_ex31z1.htm Edgar Link pending
hyex_ex31z2.htm Edgar Link pending
hyex-20230630_cal.xml Edgar Link unprocessable
hyex-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
hyex-20230630_lab.xml Edgar Link unprocessable
hyex-20230630_pre.xml Edgar Link unprocessable
hyex-20230630_htm.xml Edgar Link completed
hyex_ex32z1.htm Edgar Link pending
hyex_ex32z2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending